Thus, androgen deprivation therapy, which controls androgen-dependent tumor growth initially, may ultimately contribute to progression to castration resistance through the ability of hypoxia-induced HIF-1α to promote angiogenesis, EMT, metastasis and chemoresistance, as well as androgen receptor (AR) signaling [52, 53]. This evidence concerns the gene AR and neoplasm.